Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Gamaliel Batalla

Pain Medicine Massillon, OH Medical Doctor

NPI 1649341983 CMS profile 301534

7337 Caritas Cirle Nw, Ste 100, Massillon, OH 44646

Open in the dashboard

General payments

$4,996

303 records reported · program years 2019–2024

Research payments

$150

Paid to them · 1 record reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Gamaliel Batalla of Massillon, OH is reported in the CMS Open Payments database as having received $4,996 across 303 general payments and $150 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $90 2
2022 General $202 12
2021 General $1,231 96
2020 General $1,333 72
2020 Research $150 1
2019 General $2,140 121

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gamaliel Batalla
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Gamaliel Batalla were reported at $0. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Gamaliel Batalla Pain Medicine median Middle half National median
2019 $2,140 $498 $126–$1,682 $163
2020 $1,333 $284 $80–$910 $114
2021 $1,231 $399 $112–$1,219 $132
2022 $202 $455 $137–$1,484 $149
2023 $0 $484 $128–$1,495 $160
2024 $90 $498 $131–$1,540 $164
2025 $0 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Collegium Pharmaceutical, Inc. $574 59 payments
  2. Teva Pharmaceuticals USA, Inc. $573 37 payments
  3. Scilex Pharmaceuticals Inc. $444 22 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $319 23 payments
  5. Flexion Therapeutics, Inc. $310 14 payments
  6. Nevro Corp. $273 5 payments
  7. Pfizer Inc. $267 30 payments
  8. Amgen Inc. $253 7 payments
  9. Medtronic USA, Inc. $216 6 payments
  10. AbbVie, Inc. $209 14 payments
  11. Other $1,558 86 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $4,959 301 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $25 1 payment
  3. Education $12 1 payment
Products named General payments · program years 2019–2024
  1. XTAMPZA $574 59 payments
  2. AIMOVIG $375 18 payments
  3. Zilretta $310 14 payments
  4. RELISTOR $289 21 payments
  5. AUSTEDO $255 26 payments
  6. Senza Spinal Cord Stimulation System $254 4 payments
  7. ZTLido $235 8 payments
  8. AJOVY $199 10 payments
  9. ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH $190 13 payments
  10. SUBLOCADE $146 7 payments
  11. Other $2,290 149 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Indivior Inc. $150 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

192

Median for Pain Management: 951

Drug cost

$2,697

Median for Pain Management: $26,034

Branded share of claims

19.8%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 47 $638
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 23 $462
Methocarbamol Generic 21 $416
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 15 $337
Pregabalin Generic 21 $305
Tizanidine Hcl Generic 33 $282
Cyclobenzaprine Hcl Generic 32 $256

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$74,185

Of which drugs: $423

Medicare patients

230

Average age 71

Services billed

3,298

130 women, 100 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 49%
Ischemic heart disease 34%
Chronic kidney disease 30%
COPD 26%
Heart failure 23%
Depression 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 68 1,597 $141
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 61 336 $93
Infusion, normal saline solution, sterile (500 ml = 1 unit) J7040 Office 23 30 $31
Injection, midazolam hydrochloride, per 1 mg J2250 Office 12 23 $2

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

304 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record